Campbell's
CPB
$21.15
+0.19%
Campbell Soup Company is a leading domestic packaged food manufacturer with a diversified portfolio that extends well beyond its iconic canned soups. The company operates in the Consumer Defensive sector's Packaged Foods industry, with major segments including Baked Snacks (43% of fiscal 2025 revenue), Soups (27%), Other Simple Meals (23%), and Beverages (7%), and owns well-known brands like Pepperidge Farm, Goldfish, Snyder's of Hanover, Prego, and the recently acquired Rao's. As a legacy staple food producer, Campbell's is a mature market leader but faces intense competition and shifting consumer preferences. The current investor narrative is dominated by concerns over deteriorating financial performance, a shrinking market capitalization, and the looming risk of being demoted from the S&P 500 index after a 67-year tenure, which has cast a significant overhang on the stock.…
CPB
Campbell's
$21.15
Related headlines
Investment Opinion: Should I buy CPB Today?
Rating: Hold. The core thesis is that CPB is a deeply challenged but cash-generative company where significant fundamental risks are balanced by a high yield and depressed valuation, making it unsuitable for most investors except highly patient, income-oriented contrarians.
Supporting evidence includes a forward P/E of 11.49x, suggesting the market expects modest earnings recovery, and a Price-to-Sales ratio of 0.94x, indicating a sales-based discount. However, these are offset by a -4.51% revenue decline and gross margin compression of 256 bps. The high 4.77% dividend yield is supported by a 76.25% payout ratio and $919M in annual FCF, but analyst sentiment is uniformly cautious, with 7 analysts maintaining Hold or Sell ratings, reflecting a lack of near-term catalysts.
The biggest risks are a further acceleration in revenue decline and a dividend cut triggered by earnings pressure. This Hold rating would upgrade to a Buy only if quarterly revenue growth turns positive and gross margins stabilize above 30%. It would downgrade to a Sell if revenue decline accelerates beyond -6% YoY or if the dividend payout ratio exceeds 90%. Relative to its own history and the challenged fundamentals, the stock is fairly valued, as the low multiples adequately reflect the elevated risks.
Sign up to view all
CPB 12-Month Price Forecast
CPB is a classic 'value trap' scenario. The stock is cheap for a reason, with clear evidence of a business in secular decline, as shown by shrinking sales and margins. The high dividend yield offers compensation, but the risk of a cut is real if operational trends worsen. The neutral stance reflects the balance between these offsetting forces. The stance would upgrade to bullish only on clear evidence of top-line stabilization and margin recovery for two consecutive quarters. It would downgrade to bearish upon confirmation of S&P 500 removal or a dividend cut announcement, either of which would likely catalyze the next leg down.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Campbell's's 12-month outlook, with a consensus price target around $27.49 and implied upside of +30.0% versus the current price.
Average Target
$27.49
7 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
7
covering this stock
Price Range
$17 - $27
Analyst target range
Analyst sentiment is neutral to bearish, with limited coverage from 7 analysts. The consensus recommendation, inferred from recent institutional ratings, leans heavily towards Hold/Sector Perform or Sell/Underperform, with no recent Buy ratings cited. Firms like UBS, BofA Securities, and Barclays maintain Sell or Underweight stances, while Deutsche Bank, TD Cowen, RBC Capital, Stifel, Morgan Stanley, and DA Davidson all have Hold, Sector Perform, Equal Weight, or Neutral ratings. This distribution indicates a lack of bullish conviction, with analysts likely concerned about the company's deteriorating fundamentals and S&P 500 demotion risk. The average EPS estimate for the upcoming period is $2.13, with a range from $2.09 to $2.32. The wide target price range from analysts (implied but not explicitly provided in the data) typically signals high uncertainty around the company's future performance, with low targets pricing in continued market share loss and margin compression, while high targets might assume a successful turnaround or stabilization. The limited number of covering analysts and the uniformly cautious stance underscore the stock's status as a contrarian, high-yield play with significant fundamental challenges.
Bulls vs Bears: CPB Investment Factors
The bear case currently holds stronger evidence, anchored by concrete deterioration in revenue (-4.51% YoY) and margins (gross margin down 256 bps). While the bull case rests on a deep valuation discount (forward P/E of 11.49x) and a high, covered dividend yield, these are defensive attributes rather than growth catalysts. The single most important tension in the investment debate is whether the company's robust $919M free cash flow can fund a successful operational turnaround before its high financial leverage (D/E of 1.85) and S&P 500 demotion risk trigger further capital flight. The stock's extreme 44.35% maximum drawdown and uncorrelated beta of 0.01 underscore its status as a high-risk, company-specific story.
Bullish
- Deep Valuation Discount: CPB trades at a forward P/E of 11.49x, a significant discount to its trailing P/E of 15.98x, implying the market expects an earnings recovery. Its P/S ratio of 0.94x is also near historical lows, suggesting substantial pessimism is priced in, offering a margin of safety.
- Strong Free Cash Flow Generation: Despite operational challenges, the company generated $919 million in trailing twelve-month free cash flow. This robust cash generation supports its high dividend yield of 4.77% and provides a cushion to service its debt, mitigating near-term liquidity risks.
- High Dividend Yield with Payout Coverage: The stock offers a compelling 4.77% dividend yield, which is sustainable given a payout ratio of 76.25%. This high yield provides a tangible return while investors wait for a potential turnaround, making it attractive for income-focused portfolios.
- Oversold Technical Bounce Potential: The stock is up 12.09% over the past month, showing a positive divergence from its severe 31.54% one-year decline. Trading near 67% of its 52-week high-to-low range, it exhibits signs of an oversold bounce, which could attract short-term value buyers.
Bearish
- Persistent Revenue Contraction: Revenue declined 4.51% YoY in the latest quarter to $2.564B, following a sequential drop from $2.677B. This consistent top-line pressure across its snack, soup, and beverage segments indicates deep-seated market share loss and competitive challenges.
- Severe Margin Compression: Gross margin contracted to 27.96% from 30.52% YoY, while operating margin fell to 10.61% from 13.18%. This 250+ basis point erosion in profitability highlights intense cost pressures and an inability to pass costs to consumers, threatening future earnings.
- Elevated Financial Leverage: With a debt-to-equity ratio of 1.85, the company carries significant financial risk for a mature consumer staples firm. This high leverage limits strategic flexibility and increases vulnerability to rising interest rates or further earnings declines.
- S&P 500 Demotion Overhang: The stock faces a looming risk of being removed from the S&P 500 after 67 years due to deteriorating financials and a shrinking $6.3B market cap. This would trigger forced selling by index funds, creating a persistent overhang on the share price.
CPB Technical Analysis
The stock is in a pronounced and sustained downtrend, having lost 31.54% over the past year. As of the latest close at $22.81, the price is trading near the bottom of its 52-week range, at approximately 67% of the distance from its 52-week high of $34.17 to its low of $19.56, indicating significant technical weakness and positioning it as a potential value trap rather than a clear opportunity. The stock's beta of 0.01 suggests its price action has been almost entirely uncorrelated with the broader market, which has rallied 22.86% over the same period, highlighting severe company-specific underperformance. Recent momentum shows a modest short-term recovery attempt, with the stock up 12.09% over the past month, though this follows a sharp, multi-month decline where it lost 20.63% over the prior six months. This 1-month positive divergence from the longer-term downtrend could signal a potential oversold bounce or a brief consolidation, but it remains within the context of the broader bearish trend. Key technical levels are clearly defined, with immediate resistance at the 52-week high of $34.17 and support at the 52-week low of $19.56. A decisive break below the $19.56 support could trigger a new leg down, while a sustained move above the recent recovery highs near $29.49 is needed to suggest a meaningful trend reversal. The stock's extreme volatility relative to the market is underscored by its staggering 44.35% maximum drawdown, demanding careful risk management from any prospective buyer.
Beta
0.01
0.01x market volatility
Max Drawdown
-44.0%
Largest decline past year
52-Week Range
$20-$34
Price range past year
Annual Return
-33.6%
Cumulative gain past year
| Period | CPB Return | S&P 500 |
|---|---|---|
| 1m | +4.7% | +1.8% |
| 3m | +0.4% | +15.1% |
| 6m | -26.0% | +9.7% |
| 1y | -33.6% | +25.0% |
| ytd | -23.7% | +9.5% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CPB Fundamental Analysis
Campbell's is experiencing a clear revenue contraction and growth deceleration. For the most recent quarter (ending February 1, 2026), revenue was $2.564 billion, representing a year-over-year decline of 4.51%. This follows a sequential decline from the prior quarter's $2.677 billion, indicating persistent top-line pressure. The company's segment data shows Baked Snacks contributed $995 million, Soups $821 million, and Beverages $748 million for a recent period, but without growth rates, the data suggests a challenged sales environment across its portfolio. The company remains profitable but with compressed margins; Q2 FY2026 net income was $145 million on revenue of $2.564 billion, yielding a net margin of 5.66%. Gross margin for the quarter was 27.96%, a decline from the 30.52% reported in the same quarter the prior year, indicating rising input costs or pricing pressure. Operating income of $272 million resulted in an operating margin of 10.61%, also down from 13.18% in the year-ago quarter, showing profitability is under strain. The balance sheet shows elevated leverage with a debt-to-equity ratio of 1.85, indicating significant financial risk for a mature consumer staples company. However, the company continues to generate substantial cash, with trailing twelve-month free cash flow of $919 million. The current ratio of 0.77 suggests potential short-term liquidity constraints, but the robust free cash flow provides some cushion to service its debt and maintain its dividend, evidenced by a payout ratio of 76.25%.
Quarterly Revenue
$2.6B
2026-02
Revenue YoY Growth
-0.04%
YoY Comparison
Gross Margin
+0.27%
Latest Quarter
Free Cash Flow
$919000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CPB Overvalued?
Given a positive net income, the primary valuation metric is the Price-to-Earnings (P/E) ratio. The trailing P/E stands at 15.98x, while the forward P/E is 11.49x. The discount from trailing to forward P/E implies the market expects earnings to recover, though this expectation is tempered by recent fundamental weakness. Compared to the provided valuation data, Campbell's trades at a Price-to-Sales (P/S) ratio of 0.94x and an EV/EBITDA of 10.60x, but without industry averages for direct comparison, we must infer. Typically, packaged food peers trade at higher P/S multiples, suggesting CPB may be at a discount on a sales basis. The stock's valuation is near the lower end of its own historical range; for instance, its P/E ratio has fluctuated from as low as 11.49x (forward) to over 40x in recent quarters, and its P/S of 0.94x is significantly below the 3.20x reported in the Q2 2026 historical data. Trading near historical valuation lows suggests the market has priced in considerable pessimism regarding growth and margin prospects, potentially offering a margin of safety if the company can stabilize its operations.
PE
16.0x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -1164x~40x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
10.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are pronounced. The company's revenue is contracting at a 4.51% YoY rate, while gross margins have compressed by 256 basis points year-over-year, indicating a deteriorating core business model. With a debt-to-equity ratio of 1.85, financial leverage is high for a defensive staple, increasing interest expense sensitivity. Although free cash flow of $919M provides a buffer, a current ratio of 0.77 signals potential short-term liquidity constraints if the operating environment worsens.
Market & Competitive Risks are elevated. The stock trades at a forward P/E of 11.49x, which may seem cheap but reflects justified pessimism given the growth trajectory. The looming threat of S&P 500 index demotion, as highlighted in recent news following Lamb Weston's removal, poses a specific, non-fundamental risk that could trigger substantial forced selling by passive funds. Furthermore, the stock's beta of 0.01 indicates it has not participated in the market's 22.86% rally over the past year, highlighting severe company-specific underperformance and investor abandonment.
Worst-Case Scenario involves a continuation of current trends leading to a liquidity crisis. A sequence of further revenue declines, margin compression, and a credit rating downgrade could strain the company's ability to service its debt, forcing a dividend cut. This would break the primary bull thesis, leading to a re-rating lower. The realistic downside is to the 52-week low of $19.56, representing a potential loss of approximately -14% from the current price of $22.81. A breach of this support could trigger a steeper decline towards the $17-$18 range, mirroring the stock's 44.35% maximum drawdown.
FAQ
The key risks are, in order of severity: 1) Operational Deterioration: Persistent revenue decline and margin compression, as seen in the -4.51% YoY sales drop and 256 bps gross margin contraction. 2) Financial Leverage: A high debt-to-equity ratio of 1.85 increases vulnerability to interest rate hikes and limits strategic options. 3) Index Demotion: The imminent risk of being removed from the S&P 500, which would trigger forced selling by passive funds. 4) Dividend Cut: If free cash flow of $919M declines significantly, the current 76.25% payout ratio could become unsustainable, breaking the core investment thesis.
The 12-month forecast presents three scenarios. The Base Case (60% probability) sees the stock trading between $22 and $26, as the company muddles through with slight revenue declines but maintains its dividend. The Bull Case (20% probability), targeting $29.49 to $34.17, requires a successful operational turnaround and avoiding S&P 500 demotion. The Bear Case (20% probability), targeting the 52-week low of $19.56 to $21, involves accelerated decline and a potential dividend cut. The Base Case is most likely, predicated on the assumption that current challenging trends persist without a major new negative catalyst.
CPB appears statistically undervalued based on traditional multiples. Its forward P/E of 11.49x and Price-to-Sales ratio of 0.94x are near historical lows and below many packaged food peers. However, this discount is justified by its negative growth profile and margin pressures. The market is effectively pricing in a continued decline, implying the stock is fairly valued relative to its fundamentals. It is not a clear bargain unless the operational decline halts, at which point the low multiples would represent true undervaluation.
CPB is a high-risk, speculative buy only for a specific type of investor. It offers a compelling 4.77% dividend yield and trades at a depressed forward P/E of 11.49x, suggesting much bad news is priced in. However, with revenue declining -4.51% YoY and margins compressing, the fundamental business is deteriorating. It could be a good buy for a very patient, income-oriented contrarian who can stomach the 44.35% maximum drawdown risk and the potential for S&P 500 demotion. For most investors seeking growth or stability, it is not a good buy.
CPB is unsuitable for short-term trading due to its low beta (0.01) and lack of correlation with market rallies, which means it offers little momentum. Its high volatility and company-specific news flow (like S&P 500 decisions) make it unpredictable in the short run. For long-term investment, it is only suitable for investors with a multi-year horizon who are betting on a eventual turnaround or acquisition, and who are primarily motivated by collecting the high dividend yield while they wait. A minimum holding period of 3-5 years is suggested to ride out the volatility and allow for any potential recovery narrative to play out.